Innovative Medicines Canada

Innovative Medicines Canada
FormationApril 1914; 110 years ago (1914-04)
HeadquartersOttawa, Ontario
President
Cole Pinnow
AffiliationsHealth Research Foundation
Websitehttps://innovativemedicines.ca/
Formerly called
Canadian Association of Manufacturers of Medicinal and Toilet Products (1914-1915)

Canadian Pharmaceutical Manufacturers Association (1915-1965)

Pharmaceutical Manufacturers Association of Canada (1965-1999)

Canada’s Research-Based Pharmaceutical Companies (1999-2016)

Innovative Medicines Canada (IMC) is a national association of pharmaceutical companies that represents the interests of the research-based pharmaceutical industry in Canada. Its membership includes biopharmaceutical companies, vaccine developers, and manufacturers of medical devices, and works with government agencies, insurance companies, healthcare professionals and other stakeholders in the regulation and promotion of medicines.[1][2]

IMC is headquartered in Ottawa, Ontario, and its board of directors is chaired by Pfizer Canada President Cole Pinnow.[3][4]

History

[edit]

In April 1914, representatives from ten Canadian pharmaceutical and personal hygiene companies founded the Canadian Association of Manufacturers of Medicinal and Toilet Products.[5] The organization initially accepted individuals as members as opposed to companies themselves, with the original membership including leading figures from Frederick Stearns & Company, F.W. Horner, John Wyeth & Bros., Toronto Pharmacal, Parke, Davis & Co., Seely Manufacturing, Charles E. Frosst & Co., National Drug & Chemical Co., Lyman Bros. & Co., and Henry K. Wampole & Co.

In 1915, the organization changed its name to the Canadian Pharmaceutical Manufacturers Association, and by 1924 had established separate divisions for pharmaceuticals, perfumes and physician supplies.[6] The name was changed again in 1965 to the Pharmaceutical Manufacturers Association of Canada (PMAC), and to Canada’s Research-Based Pharmaceutical Companies (Rx&D) in 1999.[7] Finally, in 2016, the name Innovative Medicines Canada was introduced.[8]

In 2020, IMC contested price regulation reforms introduced by Government of Canada that would require increased financial reporting from pharmaceutical companies, while simultaneously reducing reporting requirements related to veterinary medicines, over-the-counter drugs and most generic medicines.[9][10]

Cole Pinnow, President of Pfizer Canada, was announced as the new chair of IMC's Board of Directors in November 2021.[3] In April 2022, IMC implemented a revised Code of Ethical Practices that included significant changes aimed to reduce the promotional nature of its educational programs.[11]

Organization

[edit]

IMC is represented on the board of directors for the Pharmaceutical Advertising Advisory Board (PAAB) by Crawford Wright, head of compliance at EMD Serono.[12]

Membership

[edit]

Current members

[edit]

Members of IMC as of May 2022 include:[13]

Former members

[edit]

Former members include Actelion, Almirall, Eisai, Ferring Pharmaceuticals, Genome Canada, ProMetic Life Sciences, Purdue Pharma, Sanofi Pasteur, Shire, and Therapure BioPharma.[14][15][16]

Health Research Foundation

[edit]

Canada’s Health Research Foundation (HRF) is a non-profit organization that invests in health research in Canadian academic centres, and promotes the benefits and values of research-driven health innovation in Canada. Innovative Medicines Canada members pay an annual contribution of $1 million to the Foundation.[17]

References

[edit]
  1. ^ Innovative Medicines Canada (2021-08-06). "Written submission for the pre-budget consultations in advance of the upcoming 2022 federal budget" (PDF). House of Commons of Canada. Archived (PDF) from the original on 2022-03-16. Retrieved 2022-08-28.
  2. ^ "Innovative Medicines Canada". Research Canada. Archived from the original on 2022-08-28. Retrieved 2022-08-28.
  3. ^ a b Brophy, Erin (2021-11-23). "Innovative Medicines Canada Introduces New Chair, Cole Pinnow". Life Sciences British Columbia. Archived from the original on 2022-08-28. Retrieved 2022-08-28.
  4. ^ "Cole Pinnow Biography" (PDF). Canadian Chamber of Commerce. April 2021. Archived (PDF) from the original on 2022-08-28. Retrieved 2022-08-28.
  5. ^ "About". Innovative Medicines Canada. Archived from the original on 2022-06-19. Retrieved 2022-08-28.
  6. ^ Gouvernement du Canada, Services publics et Approvisionnement Canada (2019-09-30). "CANADIAN ASSOCIATION MANUFACTURERS MEDICINAL TOILET PRODUCTS [1 fiche]". TERMIUM Plus (in French). Archived from the original on 2022-08-28. Retrieved 2022-08-28.
  7. ^ "Innovative Medicines Canada (IMC) updates its Code of Ethical Practices". Licks Attorneys' Compliance Blog. 2022-03-27. Archived from the original on 2022-08-28. Retrieved 2022-08-28.
  8. ^ Lougheed, Tim (2017-05-01). "New Prescription". The Chemical Institute of Canada. Archived from the original on 2022-08-28. Retrieved 2022-08-28.
  9. ^ Macnab, Aidan (2022-08-25). "COVID pandemic highlighted Canada's unique pharmaceutical IP protection regime: lawyer". Canadian Lawyer. Archived from the original on 2022-08-26. Retrieved 2022-08-28.
  10. ^ "Innovative Medicines Canada v. Canada (Attorney General)". CanLII. 2020-06-29. Retrieved 2022-08-28.
  11. ^ Vanderveken, Mark; Jospé, Dara; Saragosa, Eric (2022-02-03). "Updated Industry Code: Innovative Medicines Canada Publishes Its 2022 Code of Ethical Practices". Fasken. Archived from the original on 2022-08-30. Retrieved 2022-08-30.
  12. ^ "About". Pharmaceutical Advertising Advisory Board / Conseil Consultatif de Publicité Pharmaceutique. Archived from the original on 2018-09-24. Retrieved 2022-08-28.
  13. ^ "Member Companies". Innovative Medicines Canada. 2021. Archived from the original on 2022-05-31. Retrieved 2022-08-28.{{cite web}}: CS1 maint: unfit URL (link)
  14. ^ Fralick, Pamela; Miller, Ronnie (May 2020). "Annual Report 2019" (PDF). IMC Annual Report. Archived (PDF) from the original on 2022-08-28. Retrieved 2022-08-28.
  15. ^ Williams, Russell; Helou, John (November 2015). "Rx&D 2015 Annual Report" (PDF). Innovative Medicines Canada. Archived (PDF) from the original on 2022-01-20. Retrieved 2022-08-28.
  16. ^ Campbell, Elaine; Tremblay, Michael (2017-01-01). "2016 Annual Report" (PDF). Innovative Medicines Canada. Archived (PDF) from the original on 2022-08-28. Retrieved 2022-08-28.
  17. ^ "About". Health Research Foundation. Archived from the original on 2022-01-04. Retrieved 2022-08-28.{{cite web}}: CS1 maint: unfit URL (link)
Retrieved from "https://en.wikipedia.org/w/index.php?title=Innovative_Medicines_Canada&oldid=1208968471"